Table 1.
Baseline characteristics of the Lp(a) Cohort and LDL-C Cohort*
| Characteristic | Lp(a) Cohort (N=1296) | LDL-C Cohort (N=5184) |
|---|---|---|
| Age (years) | 57.0 (46.0-67.0) | 59.0 (48.0-70.0) |
| Women | 649 (50.1%) | 2853 (55.0%) |
| Hispanic | 16 (1.2%) | 103 (2.0%) |
| Non Hispanic Black | 254 (19.6%) | 1350 (26.0%) |
| Non Hispanic White | 930 (71.8%) | 3394 (65.5%) |
| Non Hispanic Other | 73 (5.6%) | 245 (4.7%) |
| Unknown/Not Reported | 23 (1.8%) | 92 (1.8%) |
| Insurance | ||
| Private | 382/1084 (35.2%) | 1473/4809 (30.6%) |
| Public | 357/1084 (32.9%) | 2042/4809 (42.5%) |
| Self-Pay | 10/1084 (0.9%) | 97/4809 (2.0%) |
| Other | 335/1084 (30.9%) | 1197/4809 (24.9%) |
| ASCVD Risk Score (n) | 364 | 2747 |
| Median 10 year Risk (Q1, Q3) | 0.06 (0.03-0.12) | 0.08 (0.03-0.16) |
| Prior ASCVD‡ | 629/1296 (48.5%) | 1338/5181 (25.8%) |
| Hypertension | 735/1296 (56.7%) | 3246/5181 (62.7%) |
| Hyperlipidemia | 938/1296 (72.4%) | 3341/5181 (64.5%) |
| Diabetes mellitus | 312/1296 (24.1%) | 1443/5181 (27.9%) |
| MI | 142/1296 (11.0%) | 281/5181 (5.4%) |
| MI within 12 months of index | 92/1296 (7.1%) | 112/5181 (2.2%) |
| Coronary Revascularization | 183/1296 (14.1%) | 382/5181 (7.4%) |
| CAD | 341/1296 (26.3%) | 830/5181 (16.0%) |
| Ischemic Stroke | 302/1296 (23.3%) | 308/5181 (5.9%) |
| PAD | 169/1296 (13.0%) | 462/5181 (8.9%) |
| CKD, Stage 3 or 4 | 217/1296 (16.7%) | 999/5184 (19.3%) |
| Dialysis | 19/1296 (1.5%) | 83/5181 (1.6%) |
| MI at a young age† | 83/1296 (6.4%) | 88/5181 (1.7%) |
| Coronary Revascularization at a young age† | 87/1296 (6.7%) | 103/5181 (2.0%) |
| IS at a young age† | 149/1296 (11.5%) | 80/5181 (1.5%) |
| Multiple prior CV events | 350/1296 (27.0%) | 421/5181 (8.1%) |
| Cancer | 29/1296 (2.2%) | 122/5181 (2.4%) |
| Labs and Vitals | ||
| Systolic blood pressure (mmHg) | 126.0 (115.0-140.0) | 124.0 (114.0-136.0) |
| Diastolic blood pressure (mmHg) | 76.0 (69.0-83.0) | 74.0 (68.0-80.0) |
| EGFR | 57.0 (50.0-78.0) | 57.0 (49.0-78.0) |
| Total Cholesterol (mg/dL) | 185 (149-229) | 180 (153-211) |
| HDL-C (mg/dL) | 47 (38.0-57.0) | 48 (39-60) |
| LDL-C (mg/dL) | 110 (79-146) | 103 (79-128) |
| Triglycerides (mg/dL) | 109 (76-165) | 113 (78-165) |
| Medications | ||
| Statin | 775 (59.8%) | 2129 (41.1%) |
| Statin+Ezetimibe combo | 90 (6.9%) | 82 (1.6%) |
| Ezetimibe monotherapy | 114 (8.8%) | 111 (2.1%) |
| PCSK9i | 16 (1.2%) | 8 (0.2%) |
| Niacin | 67 (5.2%) | 48 (0.9%) |
| ACEi/ARB | 607 (46.8%) | 2363 (45.6%) |
| Beta Blocker | 482 (37.2%) | 1483 (28.6%) |
| Aspirin | 635 (49.0%) | 1167 (22.5%) |
| No Lipid Lowering Therapy | 476 (36.7%) | 3010 (58.1%) |
| Encounter Type | ||
| Outpatient | 1015/1290 (78.7%) | 4758/5169 (92.0%) |
| Inpatient or ED | 275/1290 (21.3%) | 411/5169 (8.0%) |
Continuous variables reported as median and interquartile range (IQR), binary and categorical variables reported as frequencies and percentages.
Myocardial infarction, ischemic stroke and coronary revascularization were defined as occurring “at a young age” if the corresponding ICD codes were present in a male under 55 years or a female under 65 years.
Prior ASCVD includes: prior history of coronary artery disease, myocardial infarction, coronary artery bypass, percutaneous coronary intervention, peripheral artery disease, lower extremity amputation, claudication, carotid artery stenosis, peripheral revascularization, cerebrovascular accident or ischemic stroke
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; MI, myocardial infarction; CAD, coronary artery disease; PAD, peripheral artery disease; CKD, chronic kidney disease; IS, ischemic stroke; CV, cardiovascular; EGFR, estimated glomerular filtration rate; LDL-C, calculated low density lipoprotein; HDL-C, calculated high density lipoprotein; PCSK9i, proprotein convertase subtilisin 9 inhibitor; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ED, emergency department